SEARCH

SEARCH BY CITATION

References

  • 1
    Jemal A,Siegel R,Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 7196.
  • 2
    Seiwert TY,Salama JK,Vokes EE. The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol. 2007; 4: 156171.
  • 3
    Argiris A,Li Y,Forastiere A. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck: an analysis of 2 Eastern Cooperative Oncology Group randomized trials. Cancer. 2004; 101: 22222229.
  • 4
    Leon X,Hitt R,Constenla M, et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol (R Coll Radiol). 2005; 17: 418424.
  • 5
    American Cancer Society. Cancer Facts and Figures 2008. Atlanta, Ga: American Cancer Society; 2008.
  • 6
    Gillison ML,Koch WM,Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000; 92: 709720.
  • 7
    Fakhry C,Westra W,Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008; 100: 261269.
  • 8
    Gillison ML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol. 2004; 31: 744754.
  • 9
    Soria JC,Kim ES,Fayette J,Lantuejoul S,Deutsch E,Hong WK. Chemoprevention of lung cancer. Lancet Oncol. 2003; 4: 659669.
  • 10
    Posner MR,Hershock DM,Blaiman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007; 357: 17051715.
  • 11
    Vermorken JB,Remenar E,van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007; 357: 16951704.
  • 12
    Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer. 2004; 11: 689708.
  • 13
    Normanno N,De Luca A,Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006; 366: 216.
  • 14
    Ang KK,Berkey BA,Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002; 62: 73507356.
  • 15
    Grandis JR,Melhem MF,Barnes EL,Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-a and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer. 1996; 78: 2841292.
  • 16
    Ke LD,Adler-Storthz K,Clayman GL,Yung AW,Chen Z. Differential expression of epidermal growth factor receptor in human head and neck cancers. Head Neck. 1998; 20: 320327.
  • 17
    Shin DM,Ro JY,Hong WK,Hittelman WN. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res. 1994; 54: 31533159.
  • 18
    Grandis JR,Melhem MF,Gooding WE, et al. Levels of TGF-a and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998; 90: 824832.
  • 19
    Kim ES,Kies M,Herbst RS. Novel therapeutics for head and neck cancer. Curr Opin Oncol. 2002; 14: 334342.
  • 20
    Sok JC,Coppelli FM,Thomas SM, et al. Mutant epidermal growth factor receptor (EGFRVIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res. 2006; 12: 50645073.
  • 21
    Baselga J,Pfister D,Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 2000; 18: 904914.
  • 22
    Huang SM,Bock JM,Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999; 59: 19351940.
  • 23
    Mendelsohn J,Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003; 21: 27872799.
  • 24
    Dittmann K,Mayer C,Fehrenbacher B, et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem. 2005; 280: 3118231189.
  • 25
    Huang SM,Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res. 2000; 6: 21662174.
  • 26
    Milas L,Fan Z,Andratschke NH,Ang KK. Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int J Radiat Oncol Biol Phys. 2004; 58: 966971.
  • 27
    Baselga J,Norton L,Masui H, et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst. 1993; 85: 13271333.
  • 28
    Fan Z,Baselga J,Masui H,Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 1993; 53: 46374642.
  • 29
    Kang X,Patel D,Ng S,Melchior M,Ludwig D,Hicklin D. High affinity Fc receptor binding and potent induction of antibody-dependent cellular cytotoxicity (ADCC) in vitro by anti-epidermal growth factor receptor antibody cetuximab [abstract]. Proc Am Soc Clin Oncol. 2007; 25(18S). Abstract 3041.
  • 30
    Bonner JA,Harari PM,Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354: 567578.
  • 31
    Curran D,Giralt J,Harari PM, et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol. 2007; 25: 21912197.
  • 32
    Pfister DG,Su YB,Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol. 2006; 24: 10721078.
  • 33
    Langer CJ,Lee JW,Patel UA, et al. Preliminary analysis of ECOG 3303: concurrent radiation (RT), cisplatin (DDP) and cetuximab (C) in unresectable, locally advanced (LA) squamous cell carcinoma of the head and neck [abstract]. J Clin Oncol. 2008; 26( May 20 suppl). Abstract 6006.
  • 34
    National Institutes of Health. Clinical trials registry. Available at: http://www.clinicaltrials.gov Accessed July 7, 2008.
  • 35
    Burtness B,Goldwasser MA,Flood W,Mattar B,Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005; 23: 86468654.
  • 36
    Bourhis J,Rivera F,Mesia R, et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2006; 24: 28662872.
  • 37
    Vermorken JB,Mesia R,Vega V. Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy—Results of a randomized phase III (EXTREME) study [abstract]. Proc Am Soc Clin Oncol. 2007; 25(18S). Abstract 6091.
  • 38
    Vermorken JB,Hitt R,Geoffrois L, et al. Cetuximab plus platinum-based therapy first-line in recurrent and/or metastatic squamous cell carcinoma of the head and neck: efficacy and safety results of a randomized phase III trial (EXTREME) [abstract]. Eur J Cancer. 2007; 324( 4 suppl): 5501.
  • 39
    Baselga J,Trigo JM,Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2005; 23: 55685577.
  • 40
    Herbst RS,Arquette M,Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. 2005; 23: 55785587.
  • 41
    Vermorken JB,Trigo J,Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007; 25: 21712177.
  • 42
    Chung CH,Mirakhur B,Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. N Engl J Med. 2008; 358: 11091117.
  • 43
    Simon J,Stewart W,Cohen EW, et al. A phase III randomized parallel-group study of gefitinib (IRESSA) versus methotrexate (IMEX) in patients with recurrent squamous cell carcinoma of the head and neck. Program and abstracts of the Annual Meeting of the American Association for Cancer Research, Los Angeles, California, April 14-18, 2007.
  • 44
    Kim ES,Kies MS,Glisson BS, et al. Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrenet/metastatic head and neck cancer [abstract]. Proc Am Soc Clin Oncol. 2007; 25(18S). Abstract 6013.
  • 45
    Abidoye OO,Cohen EE,Wong SJ, et al. A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCGB) [abstract]. Proc Am Soc Clin Oncol. 2006; 24( 18S). Abstract 5568.
  • 46
    Fernando NH,Hurwitz HI. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol. 2003; 30: 3950.
  • 47
    Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002; 29: 1518.
  • 48
    Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol. 2002; 29: 39.
  • 49
    O-charoenrat P,Rhys-Evans P,Modjtahedi H,Eccles SA. Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells. Clin Exp Metastasis. 2000; 18: 155161.
  • 50
    Ciardiello F,Troiani T,Bianco R, et al. Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multitarget anticancer therapy. Ann Oncol. 2006; 17(S7): 109114.
  • 51
    Vokes EE,Cohen EE,Mauer AM, et al. A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck [abstract]. Proc Am Soc Clin Oncol. 2005; 23(18S). Abstract 5504.
  • 52
    Williamson SK,Moon J,Huang CH, et al. A phase II trial of sorafenib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): a Southwest Oncology Group (SWOG) trial [abstract]. Proc Am Soc Clin Oncol. 2007; 25(18S). Abstract 6044.
  • 53
    Baserga R,Peruzzi F,Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer. 2003; 107: 873877.
  • 54
    Yamada Y,Goto A,Ura T, et al. Prognostic and predictive significance of insulin-like growth factor-1 receptor (IGF-1R), epidermal growth factor receptor (EGFR), and HER2 in metastatic colorectal cancer [abstract]. Proc Am Soc Clin Oncol. 2005; 23(16S). Abstract 9649.
  • 55
    Jones H,Gee J,Hutcheson I,Knowlden J,Barrow D,Nicholson R. Growth factor receptor interplay and resistance in cancer. Endocr Relat Cancer. 2006; 13: S45S51.
  • 56
    Morgillo F,Woo JK,Kim ES,Hong WK,Lee HY. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res. 2006; 66: 1010010111.
  • 57
    Savvides P,Greskovich J,Bokar J, et al. Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck [abstract]. Proc Am Soc Clin Oncol. 2007; 25(18S). Abstract 6068.
  • 58
    Morgillo F,Kim WY,Kim ES,Ciardiello F,Hong WK,Lee HY. Implication of the insulin-like growth factor-IR pathway in the resistance of nonsmall cell lung cancer cells to treatment with gefitinib. Clin Cancer Res. 2007; 13: 27952803.
  • 59
    Giaccone G,Zucali PA. Src as a potential therapeutic target in nonsmall-cell lung cancer. Ann Oncol. 2008; 19: 12191223.
  • 60
    Johnson FM,Saigal B,Talpaz M, et al. Dasatinib (BMS-3548285) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and nonsmall cell lung cancer cell. Clin Cancer Res. 2005; 11: 69246932.
  • 61
    Adams J,Palombella V,Sausville E, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999; 59: 26152622.
  • 62
    Voorhees PM,Dees EC,O'Neil B,Orlowski RZ. The proteasome as a target for cancer therapy. Clin Cancer Res. 2003; 9: 63166325.
  • 63
    Boyle JO,Hakim J,Koch W, et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res. 1993; 53: 44774480.
  • 64
    Brennan JA,Boyle JO,Koch WM, et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med. 1995; 332: 712717.